138 related articles for article (PubMed ID: 20064714)
1. Discovery of 5-aryloxy-2,4-thiazolidinediones as potent GPR40 agonists.
Zhou C; Tang C; Chang E; Ge M; Lin S; Cline E; Tan CP; Feng Y; Zhou YP; Eiermann GJ; Petrov A; Salituro G; Meinke P; Mosley R; Akiyama TE; Einstein M; Kumar S; Berger J; Howard AD; Thornberry N; Mills SG; Yang L
Bioorg Med Chem Lett; 2010 Feb; 20(3):1298-301. PubMed ID: 20064714
[TBL] [Abstract][Full Text] [Related]
2. GPR40 partial agonist MK-2305 lower fasting glucose in the Goto Kakizaki rat via suppression of endogenous glucose production.
Miller C; Pachanski MJ; Kirkland ME; Kosinski DT; Mane J; Bunzel M; Cao J; Souza S; Thomas-Fowlkes B; Di Salvo J; Weinglass AB; Li X; Myers RW; Knagge K; Carrington PE; Hagmann WK; Trujillo ME
PLoS One; 2017; 12(5):e0176182. PubMed ID: 28542610
[TBL] [Abstract][Full Text] [Related]
3. Discovery of 3-aryl-3-ethoxypropanoic acids as orally active GPR40 agonists.
Takano R; Yoshida M; Inoue M; Honda T; Nakashima R; Matsumoto K; Yano T; Ogata T; Watanabe N; Toda N
Bioorg Med Chem Lett; 2014 Jul; 24(13):2949-53. PubMed ID: 24835985
[TBL] [Abstract][Full Text] [Related]
4. Discovery of novel orally bioavailable GPR40 agonists.
Lu H; Fei H; Yang F; Zheng S; Hu Q; Zhang L; Yuan J; Feng J; Sun P; Dong Q
Bioorg Med Chem Lett; 2013 May; 23(10):2920-4. PubMed ID: 23582779
[TBL] [Abstract][Full Text] [Related]
5. Discovery of novel benzo[b]thiophene tetrazoles as non-carboxylate GPR40 agonists.
Huang H; Winters MP; Meegalla SK; Arnoult E; Paul Lee S; Zhao S; Martin T; Rady B; Liu J; Towers M; Otieno M; Xu F; Lim HK; Silva J; Pocai A; Player MR
Bioorg Med Chem Lett; 2018 Feb; 28(3):429-436. PubMed ID: 29258772
[TBL] [Abstract][Full Text] [Related]
6. 3-Substituted 3-(4-aryloxyaryl)-propanoic acids as GPR40 agonists.
Walsh SP; Severino A; Zhou C; He J; Liang GB; Tan CP; Cao J; Eiermann GJ; Xu L; Salituro G; Howard AD; Mills SG; Yang L
Bioorg Med Chem Lett; 2011 Jun; 21(11):3390-4. PubMed ID: 21514824
[TBL] [Abstract][Full Text] [Related]
7. Activation of tongue-expressed GPR40 and GPR120 by non caloric agonists is not sufficient to drive preference in mice.
Godinot N; Yasumatsu K; Barcos ME; Pineau N; Ledda M; Viton F; Ninomiya Y; le Coutre J; Damak S
Neuroscience; 2013 Oct; 250():20-30. PubMed ID: 23831422
[TBL] [Abstract][Full Text] [Related]
8. Discovery of new dual PPARγ-GPR40 agonists with robust antidiabetic activity: Design, synthesis and in combo drug evaluation.
Hidalgo-Figueroa S; Navarrete-Vázquez G; Estrada-Soto S; Giles-Rivas D; Alarcón-Aguilar FJ; León-Rivera I; Giacoman-Martínez A; Miranda Pérez E; Almanza-Pérez JC
Biomed Pharmacother; 2017 Jun; 90():53-61. PubMed ID: 28342366
[TBL] [Abstract][Full Text] [Related]
9. AMG 837: a potent, orally bioavailable GPR40 agonist.
Houze JB; Zhu L; Sun Y; Akerman M; Qiu W; Zhang AJ; Sharma R; Schmitt M; Wang Y; Liu J; Liu J; Medina JC; Reagan JD; Luo J; Tonn G; Zhang J; Lu JY; Chen M; Lopez E; Nguyen K; Yang L; Tang L; Tian H; Shuttleworth SJ; Lin DC
Bioorg Med Chem Lett; 2012 Jan; 22(2):1267-70. PubMed ID: 22217876
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis, and biological evaluation of novel thiazolidinediones as PPARγ/FFAR1 dual agonists.
Darwish KM; Salama I; Mostafa S; Gomaa MS; Helal MA
Eur J Med Chem; 2016 Feb; 109():157-72. PubMed ID: 26774923
[TBL] [Abstract][Full Text] [Related]
11. Potentiation of insulin secretion and improvement of glucose intolerance by combining a novel G protein-coupled receptor 40 agonist DS-1558 with glucagon-like peptide-1 receptor agonists.
Nakashima R; Yano T; Ogawa J; Tanaka N; Toda N; Yoshida M; Takano R; Inoue M; Honda T; Kume S; Matsumoto K
Eur J Pharmacol; 2014 Aug; 737():194-201. PubMed ID: 24858371
[TBL] [Abstract][Full Text] [Related]
12. Discovery of Potent and Orally Bioavailable Dihydropyrazole GPR40 Agonists.
Shi J; Gu Z; Jurica EA; Wu X; Haque LE; Williams KN; Hernandez AS; Hong Z; Gao Q; Dabros M; Davulcu AH; Mathur A; Rampulla RA; Gupta AK; Jayaram R; Apedo A; Moore DB; Liu H; Kunselman LK; Brady EJ; Wilkes JJ; Zinker BA; Cai H; Shu YZ; Sun Q; Dierks EA; Foster KA; Xu C; Wang T; Panemangalore R; Cvijic ME; Xie C; Cao GG; Zhou M; Krupinski J; Whaley JM; Robl JA; Ewing WR; Ellsworth BA
J Med Chem; 2018 Feb; 61(3):681-694. PubMed ID: 29316397
[TBL] [Abstract][Full Text] [Related]
13. Discovery of Potent and Orally Bioavailable GPR40 Full Agonists Bearing Thiophen-2-ylpropanoic Acid Scaffold.
Li H; Huang Q; Chen C; Xu B; Wang HY; Long YQ
J Med Chem; 2017 Apr; 60(7):2697-2717. PubMed ID: 28277660
[TBL] [Abstract][Full Text] [Related]
14. The Discovery, Preclinical, and Early Clinical Development of Potent and Selective GPR40 Agonists for the Treatment of Type 2 Diabetes Mellitus (LY2881835, LY2922083, and LY2922470).
Hamdouchi C; Kahl SD; Patel Lewis A; Cardona GR; Zink RW; Chen K; Eessalu TE; Ficorilli JV; Marcelo MC; Otto KA; Wilbur KL; Lineswala JP; Piper JL; Coffey DS; Sweetana SA; Haas JV; Brooks DA; Pratt EJ; Belin RM; Deeg MA; Ma X; Cannady EA; Johnson JT; Yumibe NP; Chen Q; Maiti P; Montrose-Rafizadeh C; Chen Y; Reifel Miller A
J Med Chem; 2016 Dec; 59(24):10891-10916. PubMed ID: 27749056
[TBL] [Abstract][Full Text] [Related]
15. Discovery and development of benzo-[1,2,4]-triazolo-[1,4]-oxazepine GPR142 agonists for the treatment of diabetes.
Wilson JE; Kurukulasuriya R; Sinz C; Lombardo M; Bender K; Parker D; Sherer EC; Costa M; Dingley K; Li X; Mitelman S; Tong S; Bugianesi R; Ehrhardt A; Priest B; Ratliff K; Ujjainwalla F; Nargund R; Hagmann WK; Edmondson S
Bioorg Med Chem Lett; 2016 Jun; 26(12):2947-2951. PubMed ID: 27240550
[TBL] [Abstract][Full Text] [Related]
16. Discovery and SAR of trisubstituted thiazolidinones as CCR4 antagonists.
Allen S; Newhouse B; Anderson AS; Fauber B; Allen A; Chantry D; Eberhardt C; Odingo J; Burgess LE
Bioorg Med Chem Lett; 2004 Apr; 14(7):1619-24. PubMed ID: 15026036
[TBL] [Abstract][Full Text] [Related]
17. Discovery of novel selective GPR120 agonists with potent anti-diabetic activity by hybrid design.
Sheng R; Yang L; Zhang Y; Xing E; Shi R; Wen X; Wang H; Sun H
Bioorg Med Chem Lett; 2018 Aug; 28(15):2599-2604. PubMed ID: 29980358
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and biological evaluation of GPR40/FFAR1 agonists containing 3,5-dimethylisoxazole.
Yang L; Zhang J; Si L; Han L; Zhang B; Ma H; Xing J; Zhao L; Zhou J; Zhang H
Eur J Med Chem; 2016 Jun; 116():46-58. PubMed ID: 27054485
[TBL] [Abstract][Full Text] [Related]
19. Thiazolidinediones as antidiabetic agents: A critical review.
Nanjan MJ; Mohammed M; Prashantha Kumar BR; Chandrasekar MJN
Bioorg Chem; 2018 Apr; 77():548-567. PubMed ID: 29475164
[TBL] [Abstract][Full Text] [Related]
20. Discovery of N-arylpyrroles as agonists of GPR120 for the treatment of type II diabetes.
Winters MP; Sui Z; Wall M; Wang Y; Gunnet J; Leonard J; Hua H; Yan W; Suckow A; Bell A; Clapper W; Jenkinson C; Haug P; Koudriakova T; Huebert N; Murray WV
Bioorg Med Chem Lett; 2018 Mar; 28(5):841-846. PubMed ID: 29456108
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
